| 3.65 0.11 (3.11%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.33  |
1-year : | 6.08 |
| Resists | First : | 4.56 |
Second : | 5.21 |
| Pivot price | 3.97 |
|||
| Supports | First : | 3.52 |
Second : | 2.93 |
| MAs | MA(5) : | 3.77 |
MA(20) : | 4.06 |
| MA(100) : | 5.49 |
MA(250) : | 7.19 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 10.4 |
D(3) : | 13.4 |
| RSI | RSI(14): 39.1 |
|||
| 52-week | High : | 16.11 | Low : | 3.51 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GTBP ] has closed above bottom band by 18.9%. Bollinger Bands are 28.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.83 - 3.85 | 3.85 - 3.87 |
| Low: | 3.48 - 3.5 | 3.5 - 3.52 |
| Close: | 3.61 - 3.64 | 3.64 - 3.68 |
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
Wed, 27 Mar 2024
GT Biopharma Inc Down 3.44% To $4.33 After Earnings Beat - InvestorsObserver
Fri, 02 Feb 2024
GT Biopharma Announces 1-for-30 Reverse Stock Split - TipRanks.com - TipRanks
Fri, 02 Jun 2023
Here's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Mon, 15 Nov 2021
GT Biopharma: Therapy Strategy Shift Reduces Attractiveness (NASDAQ:GTBP) - Seeking Alpha
Mon, 13 Sep 2021
GT Biopharma Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies - PR Newswire
Wed, 07 Jul 2021
Hot Small-Cap Stocks To Watch With Potential Cancer Breakthroughs - Penny Stocks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 10.4 (%) |
| Held by Institutions | 13.4 (%) |
| Shares Short | 9 (K) |
| Shares Short P.Month | 6 (K) |
| EPS | -5.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -55.1 % |
| Return on Equity (ttm) | -79.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.66 |
| PEG Ratio | 0 |
| Price to Book value | 0.67 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|